Diabetes Care:临床和亚临床大血管疾病标志物可预测老年T2DM患者认知减退

2013-05-06 Diabetes Care dxy

大血管疾病促使2型糖尿病患者认知加速减退的风险增加。为了确定在认知健康的老年2型糖尿病患者中大血管疾病指标与认知改变的相关性,来自英国苏格兰爱丁堡大学人口健康科学中心的Price博士等人进行了一项研究,研究发现,老年2型糖尿病患者中风、亚临床心区不适标志物和全身性动脉粥样硬化与认知减退具有显著相关性。研究结果在线发表于2013年4月11日的美国《糖尿病护理》(Diabetes Care)杂志上。研

大血管疾病促使2型糖尿病患者认知加速减退的风险增加。为了确定在认知健康的老年2型糖尿病患者中大血管疾病指标与认知改变的相关性,来自英国苏格兰爱丁堡大学人口健康科学中心的Price博士等人进行了一项研究,研究发现,老年2型糖尿病患者中风、亚临床心区不适标志物和全身性动脉粥样硬化与认知减退具有显著相关性。研究结果在线发表于2013年4月11日的美国《糖尿病护理》(Diabetes Care)杂志上。
研究对象为爱丁堡2型糖尿病研究(ET2DS)中的受试者,831名男性和女性(年龄60-75岁)参加了两个阶段的研究。测定基线、临床和亚临床大血管疾病,包括心血管病史、颈动脉内膜中层厚度(cIMT)、踝肱比(ABI)、血清N末端前脑钠肽(NT-proBNP)。在基线和随访4年后对参与者实施7项神经心理测验,将认知评分与标准化的一般能力因子 (g)合并。校正随访期g的基线g,用于评价4年认知改变。校正词汇(评估病前能力)用于评价生存期内认知改变。
结果显示,认知减退与中风、NT-proBNP、ABI、cIMT显著相关,但是与非中风性血管事件不相关。中风与估计的生存期内认知减退升高(标准回归系数β,-0.12),以及亚临床指标与实际的4年认知减退(NT-proBNP、ABI、cIMT的β分别为-0.12、0.12和-0.15)的相关性达到Bonferroni校正的统计学显著水平(P<0.006)。校正血管危险因素后,结果仅有轻微改变。
研究表明,老年2型糖尿病患者中风、亚临床心区不适标志物和全身性动脉粥样硬化与认知减退具有相关性。作者认为,使用亚临床血管疾病标志物预测认知减退仍需要进一步的研究。
糖尿病相关的拓展阅读:


Clinical and Subclinical Macrovascular Disease as Predictors of Cognitive Decline in Older Patients With Type 2 Diabetes: The Edinburgh Type 2 Diabetes Study.
OBJECTIVE
Macrovascular disease may contribute to increased risk of accelerated cognitive decline in patients with type 2 diabetes. We aimed to determine associations of measures of macrovascular disease with cognitive change in a cognitively healthy older population with type 2 diabetes.
RESEARCH
DESIGN AND METHODS Eight-hundred thirty-one men and women (aged 60–75 years) attended two waves of the prospective Edinburgh Type 2 Diabetes Study (ET2DS). At baseline, clinical and subclinical macrovascular disease was measured, including cardiovascular event history, carotid intima-media thickness (cIMT), ankle brachial index (ABI), and serum N-terminal probrain natriuretic peptide (NT-proBNP). Seven neuropsychological tests were administered at baseline and after 4 years; scores were combined to a standardized general ability factor (g). Adjustment of follow-up g for baseline g assessed 4-year cognitive change. Adjustment for vocabulary (estimated premorbid ability) was used to estimate lifetime cognitive change.
RESULTS
Measures of cognitive decline were significantly associated with stroke, NT-proBNP, ABI, and cIMT, but not with nonstroke vascular events. The association of stroke with increased estimated lifetime cognitive decline (standardized β, −0.12) and of subclinical markers with actual 4-year decline (standardized β, −0.12, 0.12, and −0.15 for NT-proBNP, ABI, and cIMT, respectively) reached the Bonferroni-adjusted level of statistical significance (P < 0.006). Results altered only slightly on adjustment for vascular risk factors.
CONCLUSIONS
Stroke and subclinical markers of cardiac stress and generalized atherosclerosis are associated with cognitive decline in older patients with type 2 diabetes. Further investigation into the potential use of subclinical vascular disease markers in predicting cognitive decline is warranted.

版权声明:
本网站所有内容来源注明为“williamhill asia 医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于williamhill asia 医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“williamhill asia 医学”。其它来源的文章系转载文章,或“williamhill asia 号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与williamhill asia 联系,williamhill asia 将立即进行删除处理。
在此留言
评论区 (11)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1799424, encodeId=997d1e9942465, content=<a href='/topic/show?id=0ceee0685e7' target=_blank style='color:#2F92EE;'>#疾病标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70685, encryptionId=0ceee0685e7, topicName=疾病标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Thu Aug 08 01:21:00 CST 2013, time=2013-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1954715, encodeId=cdbf1954e1559, content=<a href='/topic/show?id=d62991211f1' target=_blank style='color:#2F92EE;'>#认知减退#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91211, encryptionId=d62991211f1, topicName=认知减退)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Sat Feb 22 09:21:00 CST 2014, time=2014-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901078, encodeId=45b819010e8df, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Wed Oct 09 19:21:00 CST 2013, time=2013-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1957303, encodeId=0a19195e303ce, content=<a href='/topic/show?id=41d7439937f' target=_blank style='color:#2F92EE;'>#大血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43993, encryptionId=41d7439937f, topicName=大血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Tue Aug 20 14:21:00 CST 2013, time=2013-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1706096, encodeId=681f1e06096d3, content=<a href='/topic/show?id=7f6443986ec' target=_blank style='color:#2F92EE;'>#大血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43986, encryptionId=7f6443986ec, topicName=大血管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=caff31165455, createdName=kkunny, createdTime=Wed Sep 18 02:21:00 CST 2013, time=2013-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1840763, encodeId=a55c1840e63e1, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Fri Jan 31 01:21:00 CST 2014, time=2014-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1717708, encodeId=d3531e17708b8, content=<a href='/topic/show?id=f6b01e050d5' target=_blank style='color:#2F92EE;'>#T2DM患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17050, encryptionId=f6b01e050d5, topicName=T2DM患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b70c32458048, createdName=stfoxst, createdTime=Wed Nov 20 12:21:00 CST 2013, time=2013-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636657, encodeId=1bed163665e75, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Jul 13 13:21:00 CST 2013, time=2013-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759272, encodeId=42901e592725e, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Wed Apr 09 04:21:00 CST 2014, time=2014-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1799421, encodeId=5c7a1e9942117, content=<a href='/topic/show?id=b814e0684aa' target=_blank style='color:#2F92EE;'>#疾病标志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70684, encryptionId=b814e0684aa, topicName=疾病标志)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ee7414, createdName=lanyan20020086, createdTime=Thu Dec 19 13:21:00 CST 2013, time=2013-12-19, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1799424, encodeId=997d1e9942465, content=<a href='/topic/show?id=0ceee0685e7' target=_blank style='color:#2F92EE;'>#疾病标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70685, encryptionId=0ceee0685e7, topicName=疾病标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Thu Aug 08 01:21:00 CST 2013, time=2013-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1954715, encodeId=cdbf1954e1559, content=<a href='/topic/show?id=d62991211f1' target=_blank style='color:#2F92EE;'>#认知减退#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91211, encryptionId=d62991211f1, topicName=认知减退)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Sat Feb 22 09:21:00 CST 2014, time=2014-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901078, encodeId=45b819010e8df, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Wed Oct 09 19:21:00 CST 2013, time=2013-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1957303, encodeId=0a19195e303ce, content=<a href='/topic/show?id=41d7439937f' target=_blank style='color:#2F92EE;'>#大血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43993, encryptionId=41d7439937f, topicName=大血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Tue Aug 20 14:21:00 CST 2013, time=2013-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1706096, encodeId=681f1e06096d3, content=<a href='/topic/show?id=7f6443986ec' target=_blank style='color:#2F92EE;'>#大血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43986, encryptionId=7f6443986ec, topicName=大血管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=caff31165455, createdName=kkunny, createdTime=Wed Sep 18 02:21:00 CST 2013, time=2013-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1840763, encodeId=a55c1840e63e1, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Fri Jan 31 01:21:00 CST 2014, time=2014-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1717708, encodeId=d3531e17708b8, content=<a href='/topic/show?id=f6b01e050d5' target=_blank style='color:#2F92EE;'>#T2DM患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17050, encryptionId=f6b01e050d5, topicName=T2DM患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b70c32458048, createdName=stfoxst, createdTime=Wed Nov 20 12:21:00 CST 2013, time=2013-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636657, encodeId=1bed163665e75, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Jul 13 13:21:00 CST 2013, time=2013-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759272, encodeId=42901e592725e, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Wed Apr 09 04:21:00 CST 2014, time=2014-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1799421, encodeId=5c7a1e9942117, content=<a href='/topic/show?id=b814e0684aa' target=_blank style='color:#2F92EE;'>#疾病标志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70684, encryptionId=b814e0684aa, topicName=疾病标志)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ee7414, createdName=lanyan20020086, createdTime=Thu Dec 19 13:21:00 CST 2013, time=2013-12-19, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1799424, encodeId=997d1e9942465, content=<a href='/topic/show?id=0ceee0685e7' target=_blank style='color:#2F92EE;'>#疾病标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70685, encryptionId=0ceee0685e7, topicName=疾病标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Thu Aug 08 01:21:00 CST 2013, time=2013-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1954715, encodeId=cdbf1954e1559, content=<a href='/topic/show?id=d62991211f1' target=_blank style='color:#2F92EE;'>#认知减退#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91211, encryptionId=d62991211f1, topicName=认知减退)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Sat Feb 22 09:21:00 CST 2014, time=2014-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901078, encodeId=45b819010e8df, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Wed Oct 09 19:21:00 CST 2013, time=2013-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1957303, encodeId=0a19195e303ce, content=<a href='/topic/show?id=41d7439937f' target=_blank style='color:#2F92EE;'>#大血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43993, encryptionId=41d7439937f, topicName=大血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Tue Aug 20 14:21:00 CST 2013, time=2013-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1706096, encodeId=681f1e06096d3, content=<a href='/topic/show?id=7f6443986ec' target=_blank style='color:#2F92EE;'>#大血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43986, encryptionId=7f6443986ec, topicName=大血管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=caff31165455, createdName=kkunny, createdTime=Wed Sep 18 02:21:00 CST 2013, time=2013-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1840763, encodeId=a55c1840e63e1, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Fri Jan 31 01:21:00 CST 2014, time=2014-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1717708, encodeId=d3531e17708b8, content=<a href='/topic/show?id=f6b01e050d5' target=_blank style='color:#2F92EE;'>#T2DM患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17050, encryptionId=f6b01e050d5, topicName=T2DM患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b70c32458048, createdName=stfoxst, createdTime=Wed Nov 20 12:21:00 CST 2013, time=2013-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636657, encodeId=1bed163665e75, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Jul 13 13:21:00 CST 2013, time=2013-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759272, encodeId=42901e592725e, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Wed Apr 09 04:21:00 CST 2014, time=2014-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1799421, encodeId=5c7a1e9942117, content=<a href='/topic/show?id=b814e0684aa' target=_blank style='color:#2F92EE;'>#疾病标志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70684, encryptionId=b814e0684aa, topicName=疾病标志)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ee7414, createdName=lanyan20020086, createdTime=Thu Dec 19 13:21:00 CST 2013, time=2013-12-19, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1799424, encodeId=997d1e9942465, content=<a href='/topic/show?id=0ceee0685e7' target=_blank style='color:#2F92EE;'>#疾病标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70685, encryptionId=0ceee0685e7, topicName=疾病标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Thu Aug 08 01:21:00 CST 2013, time=2013-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1954715, encodeId=cdbf1954e1559, content=<a href='/topic/show?id=d62991211f1' target=_blank style='color:#2F92EE;'>#认知减退#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91211, encryptionId=d62991211f1, topicName=认知减退)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Sat Feb 22 09:21:00 CST 2014, time=2014-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901078, encodeId=45b819010e8df, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Wed Oct 09 19:21:00 CST 2013, time=2013-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1957303, encodeId=0a19195e303ce, content=<a href='/topic/show?id=41d7439937f' target=_blank style='color:#2F92EE;'>#大血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43993, encryptionId=41d7439937f, topicName=大血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Tue Aug 20 14:21:00 CST 2013, time=2013-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1706096, encodeId=681f1e06096d3, content=<a href='/topic/show?id=7f6443986ec' target=_blank style='color:#2F92EE;'>#大血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43986, encryptionId=7f6443986ec, topicName=大血管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=caff31165455, createdName=kkunny, createdTime=Wed Sep 18 02:21:00 CST 2013, time=2013-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1840763, encodeId=a55c1840e63e1, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Fri Jan 31 01:21:00 CST 2014, time=2014-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1717708, encodeId=d3531e17708b8, content=<a href='/topic/show?id=f6b01e050d5' target=_blank style='color:#2F92EE;'>#T2DM患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17050, encryptionId=f6b01e050d5, topicName=T2DM患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b70c32458048, createdName=stfoxst, createdTime=Wed Nov 20 12:21:00 CST 2013, time=2013-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636657, encodeId=1bed163665e75, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Jul 13 13:21:00 CST 2013, time=2013-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759272, encodeId=42901e592725e, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Wed Apr 09 04:21:00 CST 2014, time=2014-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1799421, encodeId=5c7a1e9942117, content=<a href='/topic/show?id=b814e0684aa' target=_blank style='color:#2F92EE;'>#疾病标志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70684, encryptionId=b814e0684aa, topicName=疾病标志)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ee7414, createdName=lanyan20020086, createdTime=Thu Dec 19 13:21:00 CST 2013, time=2013-12-19, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1799424, encodeId=997d1e9942465, content=<a href='/topic/show?id=0ceee0685e7' target=_blank style='color:#2F92EE;'>#疾病标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70685, encryptionId=0ceee0685e7, topicName=疾病标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Thu Aug 08 01:21:00 CST 2013, time=2013-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1954715, encodeId=cdbf1954e1559, content=<a href='/topic/show?id=d62991211f1' target=_blank style='color:#2F92EE;'>#认知减退#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91211, encryptionId=d62991211f1, topicName=认知减退)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Sat Feb 22 09:21:00 CST 2014, time=2014-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901078, encodeId=45b819010e8df, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Wed Oct 09 19:21:00 CST 2013, time=2013-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1957303, encodeId=0a19195e303ce, content=<a href='/topic/show?id=41d7439937f' target=_blank style='color:#2F92EE;'>#大血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43993, encryptionId=41d7439937f, topicName=大血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Tue Aug 20 14:21:00 CST 2013, time=2013-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1706096, encodeId=681f1e06096d3, content=<a href='/topic/show?id=7f6443986ec' target=_blank style='color:#2F92EE;'>#大血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43986, encryptionId=7f6443986ec, topicName=大血管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=caff31165455, createdName=kkunny, createdTime=Wed Sep 18 02:21:00 CST 2013, time=2013-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1840763, encodeId=a55c1840e63e1, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Fri Jan 31 01:21:00 CST 2014, time=2014-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1717708, encodeId=d3531e17708b8, content=<a href='/topic/show?id=f6b01e050d5' target=_blank style='color:#2F92EE;'>#T2DM患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17050, encryptionId=f6b01e050d5, topicName=T2DM患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b70c32458048, createdName=stfoxst, createdTime=Wed Nov 20 12:21:00 CST 2013, time=2013-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636657, encodeId=1bed163665e75, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Jul 13 13:21:00 CST 2013, time=2013-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759272, encodeId=42901e592725e, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Wed Apr 09 04:21:00 CST 2014, time=2014-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1799421, encodeId=5c7a1e9942117, content=<a href='/topic/show?id=b814e0684aa' target=_blank style='color:#2F92EE;'>#疾病标志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70684, encryptionId=b814e0684aa, topicName=疾病标志)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ee7414, createdName=lanyan20020086, createdTime=Thu Dec 19 13:21:00 CST 2013, time=2013-12-19, status=1, ipAttribution=)]
    2013-09-18 kkunny
  6. [GetPortalCommentsPageByObjectIdResponse(id=1799424, encodeId=997d1e9942465, content=<a href='/topic/show?id=0ceee0685e7' target=_blank style='color:#2F92EE;'>#疾病标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70685, encryptionId=0ceee0685e7, topicName=疾病标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Thu Aug 08 01:21:00 CST 2013, time=2013-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1954715, encodeId=cdbf1954e1559, content=<a href='/topic/show?id=d62991211f1' target=_blank style='color:#2F92EE;'>#认知减退#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91211, encryptionId=d62991211f1, topicName=认知减退)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Sat Feb 22 09:21:00 CST 2014, time=2014-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901078, encodeId=45b819010e8df, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Wed Oct 09 19:21:00 CST 2013, time=2013-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1957303, encodeId=0a19195e303ce, content=<a href='/topic/show?id=41d7439937f' target=_blank style='color:#2F92EE;'>#大血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43993, encryptionId=41d7439937f, topicName=大血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Tue Aug 20 14:21:00 CST 2013, time=2013-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1706096, encodeId=681f1e06096d3, content=<a href='/topic/show?id=7f6443986ec' target=_blank style='color:#2F92EE;'>#大血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43986, encryptionId=7f6443986ec, topicName=大血管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=caff31165455, createdName=kkunny, createdTime=Wed Sep 18 02:21:00 CST 2013, time=2013-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1840763, encodeId=a55c1840e63e1, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Fri Jan 31 01:21:00 CST 2014, time=2014-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1717708, encodeId=d3531e17708b8, content=<a href='/topic/show?id=f6b01e050d5' target=_blank style='color:#2F92EE;'>#T2DM患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17050, encryptionId=f6b01e050d5, topicName=T2DM患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b70c32458048, createdName=stfoxst, createdTime=Wed Nov 20 12:21:00 CST 2013, time=2013-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636657, encodeId=1bed163665e75, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Jul 13 13:21:00 CST 2013, time=2013-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759272, encodeId=42901e592725e, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Wed Apr 09 04:21:00 CST 2014, time=2014-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1799421, encodeId=5c7a1e9942117, content=<a href='/topic/show?id=b814e0684aa' target=_blank style='color:#2F92EE;'>#疾病标志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70684, encryptionId=b814e0684aa, topicName=疾病标志)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ee7414, createdName=lanyan20020086, createdTime=Thu Dec 19 13:21:00 CST 2013, time=2013-12-19, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1799424, encodeId=997d1e9942465, content=<a href='/topic/show?id=0ceee0685e7' target=_blank style='color:#2F92EE;'>#疾病标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70685, encryptionId=0ceee0685e7, topicName=疾病标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Thu Aug 08 01:21:00 CST 2013, time=2013-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1954715, encodeId=cdbf1954e1559, content=<a href='/topic/show?id=d62991211f1' target=_blank style='color:#2F92EE;'>#认知减退#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91211, encryptionId=d62991211f1, topicName=认知减退)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Sat Feb 22 09:21:00 CST 2014, time=2014-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901078, encodeId=45b819010e8df, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Wed Oct 09 19:21:00 CST 2013, time=2013-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1957303, encodeId=0a19195e303ce, content=<a href='/topic/show?id=41d7439937f' target=_blank style='color:#2F92EE;'>#大血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43993, encryptionId=41d7439937f, topicName=大血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Tue Aug 20 14:21:00 CST 2013, time=2013-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1706096, encodeId=681f1e06096d3, content=<a href='/topic/show?id=7f6443986ec' target=_blank style='color:#2F92EE;'>#大血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43986, encryptionId=7f6443986ec, topicName=大血管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=caff31165455, createdName=kkunny, createdTime=Wed Sep 18 02:21:00 CST 2013, time=2013-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1840763, encodeId=a55c1840e63e1, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Fri Jan 31 01:21:00 CST 2014, time=2014-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1717708, encodeId=d3531e17708b8, content=<a href='/topic/show?id=f6b01e050d5' target=_blank style='color:#2F92EE;'>#T2DM患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17050, encryptionId=f6b01e050d5, topicName=T2DM患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b70c32458048, createdName=stfoxst, createdTime=Wed Nov 20 12:21:00 CST 2013, time=2013-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636657, encodeId=1bed163665e75, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Jul 13 13:21:00 CST 2013, time=2013-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759272, encodeId=42901e592725e, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Wed Apr 09 04:21:00 CST 2014, time=2014-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1799421, encodeId=5c7a1e9942117, content=<a href='/topic/show?id=b814e0684aa' target=_blank style='color:#2F92EE;'>#疾病标志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70684, encryptionId=b814e0684aa, topicName=疾病标志)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ee7414, createdName=lanyan20020086, createdTime=Thu Dec 19 13:21:00 CST 2013, time=2013-12-19, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1799424, encodeId=997d1e9942465, content=<a href='/topic/show?id=0ceee0685e7' target=_blank style='color:#2F92EE;'>#疾病标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70685, encryptionId=0ceee0685e7, topicName=疾病标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Thu Aug 08 01:21:00 CST 2013, time=2013-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1954715, encodeId=cdbf1954e1559, content=<a href='/topic/show?id=d62991211f1' target=_blank style='color:#2F92EE;'>#认知减退#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91211, encryptionId=d62991211f1, topicName=认知减退)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Sat Feb 22 09:21:00 CST 2014, time=2014-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901078, encodeId=45b819010e8df, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Wed Oct 09 19:21:00 CST 2013, time=2013-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1957303, encodeId=0a19195e303ce, content=<a href='/topic/show?id=41d7439937f' target=_blank style='color:#2F92EE;'>#大血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43993, encryptionId=41d7439937f, topicName=大血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Tue Aug 20 14:21:00 CST 2013, time=2013-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1706096, encodeId=681f1e06096d3, content=<a href='/topic/show?id=7f6443986ec' target=_blank style='color:#2F92EE;'>#大血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43986, encryptionId=7f6443986ec, topicName=大血管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=caff31165455, createdName=kkunny, createdTime=Wed Sep 18 02:21:00 CST 2013, time=2013-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1840763, encodeId=a55c1840e63e1, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Fri Jan 31 01:21:00 CST 2014, time=2014-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1717708, encodeId=d3531e17708b8, content=<a href='/topic/show?id=f6b01e050d5' target=_blank style='color:#2F92EE;'>#T2DM患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17050, encryptionId=f6b01e050d5, topicName=T2DM患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b70c32458048, createdName=stfoxst, createdTime=Wed Nov 20 12:21:00 CST 2013, time=2013-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636657, encodeId=1bed163665e75, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Jul 13 13:21:00 CST 2013, time=2013-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759272, encodeId=42901e592725e, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Wed Apr 09 04:21:00 CST 2014, time=2014-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1799421, encodeId=5c7a1e9942117, content=<a href='/topic/show?id=b814e0684aa' target=_blank style='color:#2F92EE;'>#疾病标志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70684, encryptionId=b814e0684aa, topicName=疾病标志)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ee7414, createdName=lanyan20020086, createdTime=Thu Dec 19 13:21:00 CST 2013, time=2013-12-19, status=1, ipAttribution=)]
  9. [GetPortalCommentsPageByObjectIdResponse(id=1799424, encodeId=997d1e9942465, content=<a href='/topic/show?id=0ceee0685e7' target=_blank style='color:#2F92EE;'>#疾病标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70685, encryptionId=0ceee0685e7, topicName=疾病标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Thu Aug 08 01:21:00 CST 2013, time=2013-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1954715, encodeId=cdbf1954e1559, content=<a href='/topic/show?id=d62991211f1' target=_blank style='color:#2F92EE;'>#认知减退#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91211, encryptionId=d62991211f1, topicName=认知减退)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Sat Feb 22 09:21:00 CST 2014, time=2014-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901078, encodeId=45b819010e8df, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Wed Oct 09 19:21:00 CST 2013, time=2013-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1957303, encodeId=0a19195e303ce, content=<a href='/topic/show?id=41d7439937f' target=_blank style='color:#2F92EE;'>#大血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43993, encryptionId=41d7439937f, topicName=大血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Tue Aug 20 14:21:00 CST 2013, time=2013-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1706096, encodeId=681f1e06096d3, content=<a href='/topic/show?id=7f6443986ec' target=_blank style='color:#2F92EE;'>#大血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43986, encryptionId=7f6443986ec, topicName=大血管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=caff31165455, createdName=kkunny, createdTime=Wed Sep 18 02:21:00 CST 2013, time=2013-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1840763, encodeId=a55c1840e63e1, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Fri Jan 31 01:21:00 CST 2014, time=2014-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1717708, encodeId=d3531e17708b8, content=<a href='/topic/show?id=f6b01e050d5' target=_blank style='color:#2F92EE;'>#T2DM患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17050, encryptionId=f6b01e050d5, topicName=T2DM患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b70c32458048, createdName=stfoxst, createdTime=Wed Nov 20 12:21:00 CST 2013, time=2013-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636657, encodeId=1bed163665e75, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Jul 13 13:21:00 CST 2013, time=2013-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759272, encodeId=42901e592725e, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Wed Apr 09 04:21:00 CST 2014, time=2014-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1799421, encodeId=5c7a1e9942117, content=<a href='/topic/show?id=b814e0684aa' target=_blank style='color:#2F92EE;'>#疾病标志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70684, encryptionId=b814e0684aa, topicName=疾病标志)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ee7414, createdName=lanyan20020086, createdTime=Thu Dec 19 13:21:00 CST 2013, time=2013-12-19, status=1, ipAttribution=)]
  10. [GetPortalCommentsPageByObjectIdResponse(id=1799424, encodeId=997d1e9942465, content=<a href='/topic/show?id=0ceee0685e7' target=_blank style='color:#2F92EE;'>#疾病标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70685, encryptionId=0ceee0685e7, topicName=疾病标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Thu Aug 08 01:21:00 CST 2013, time=2013-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1954715, encodeId=cdbf1954e1559, content=<a href='/topic/show?id=d62991211f1' target=_blank style='color:#2F92EE;'>#认知减退#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91211, encryptionId=d62991211f1, topicName=认知减退)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Sat Feb 22 09:21:00 CST 2014, time=2014-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901078, encodeId=45b819010e8df, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Wed Oct 09 19:21:00 CST 2013, time=2013-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1957303, encodeId=0a19195e303ce, content=<a href='/topic/show?id=41d7439937f' target=_blank style='color:#2F92EE;'>#大血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43993, encryptionId=41d7439937f, topicName=大血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Tue Aug 20 14:21:00 CST 2013, time=2013-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1706096, encodeId=681f1e06096d3, content=<a href='/topic/show?id=7f6443986ec' target=_blank style='color:#2F92EE;'>#大血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43986, encryptionId=7f6443986ec, topicName=大血管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=caff31165455, createdName=kkunny, createdTime=Wed Sep 18 02:21:00 CST 2013, time=2013-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1840763, encodeId=a55c1840e63e1, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Fri Jan 31 01:21:00 CST 2014, time=2014-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1717708, encodeId=d3531e17708b8, content=<a href='/topic/show?id=f6b01e050d5' target=_blank style='color:#2F92EE;'>#T2DM患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17050, encryptionId=f6b01e050d5, topicName=T2DM患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b70c32458048, createdName=stfoxst, createdTime=Wed Nov 20 12:21:00 CST 2013, time=2013-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636657, encodeId=1bed163665e75, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Jul 13 13:21:00 CST 2013, time=2013-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759272, encodeId=42901e592725e, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Wed Apr 09 04:21:00 CST 2014, time=2014-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1799421, encodeId=5c7a1e9942117, content=<a href='/topic/show?id=b814e0684aa' target=_blank style='color:#2F92EE;'>#疾病标志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70684, encryptionId=b814e0684aa, topicName=疾病标志)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ee7414, createdName=lanyan20020086, createdTime=Thu Dec 19 13:21:00 CST 2013, time=2013-12-19, status=1, ipAttribution=)]

相关威廉亚洲官网

Excel在临床药物动力学中的应用

于广华,李信梅  (盐城市卫生学校,江苏 盐城 224001)   临床药物动力学研中,血药浓度的计算、药动学参数的求解、给药方案的设计、数据设计及组织管理、绘制图表等,需要进行大量而繁琐的数据处理、绘制各式图形。国内药动学处理软件如3987等,图形与MS Word等字处理软件不兼容,图形也不丰富。电子表格处理系统Microsoft Excel 97 for Windows是具有强大的

金冬雁教授:基础与临床的脱节是中国医学研究的深层次矛盾

     中国医学研究的一个深层次矛盾就是基础与临床研究的脱节,其中一个特点就是病理学、微生物学及免疫学的学科地位过于弱化。     谈到基础与临床研究的脱节,我体会较深也经常讲的例子,就是SARS病毒的发现。中国出现的SARS病毒,内地学者没有最早分离到,应该是中国医学病毒学界永远的痛。我知道有些人至今不服气,声称如果不是别

马军:血液肿瘤临床研究进展解读

 作者:哈尔滨血液肿瘤研究所 马军        2011 年全球各杂志发表关于恶性血液学临床研究共1.4 万多篇文章,本文就急性早幼粒细胞白血病(APL)、多发性骨髓瘤(MM)、骨髓增生异常综合征(MDS)、急性髓系白血病(AML)的临床治疗进展作一介绍。   急性早幼粒细胞白血病 &nb

王建祥:重视急性白血病非血液学表现的临床诊治

作者:中国医学科学院血液学研究所 王建祥 前言        急性白血病( AL) 是一组起源于造血干细胞的恶性克隆性疾病,其临床表现与白血病细胞大量增殖并蓄积于骨髓导致正常造血受抑及白血病细胞浸润其他组织器官有关,症状的缓急主要取决于白血病细胞在体内增长蓄积的速率和程度。化疗是彻底清除体内白血病细胞使正常造血功能得以恢复的最主要手

A&R: 接受甲氨蝶呤治疗的类风湿关节炎患者合用Tofacitinib(CP-690,550)的临床随机研究

来自荷兰莱顿大学医学中心的Desiree van der Heijde等人进行了一项研究,该项为期24周的三期研究的目的是检验Tofacitinib对甲氨蝶呤(MTX)疗效不佳的类风湿关节炎(RA)患者的关节结构的保护的作用。数据来源于第12周的中期分析报告。研究结果在线发布在2013年3月的ARTHRITIS & RHEUMATISM(关节炎与风湿病)上。研究者发现,接受MTX治疗的RA

ACP:临床常见难题的专家见解

新奥尔良(EGMN)——在新奥尔良Ernest N. Morial会展中心举行的美国医师协会(ACP)年会上,美国梅奥医院的John B. Bundrick博士受邀分享了他对临床实践的见解。  干眼症?再见  对于人工泪液不足以缓解症状的老年干眼症患者,最佳的循证辅助治疗是鱼油胶囊。  近期一项小型随机、双盲临床试验证实了鱼油补充剂对轻中度干眼症的益处。经过90